Famotidine and C. difficile Risk
Famotidine (an H2-receptor antagonist) carries a lower risk of causing C. difficile infection compared to proton pump inhibitors, though it still poses some increased risk compared to no acid suppression.
Evidence Hierarchy and Risk Assessment
The relationship between acid-suppressive medications and CDI remains somewhat controversial in the literature, but the most recent high-quality evidence provides important distinctions between drug classes:
H2-Receptor Antagonists vs PPIs
The most recent and highest quality evidence shows that H2-receptor antagonists like famotidine pose significantly less CDI risk than PPIs 1. In a 2025 large propensity-matched cohort study of over 600,000 patients, PPIs demonstrated a relative risk of 1.86 (95% CI: 1.18-2.91) for developing CDI compared to H2RAs, while H2RAs served as the reference group 1. This represents the most direct comparative evidence available.
A 2026 Swedish population-based case-control study of 42,921 CDI cases found that histamine H2-receptor antagonists were associated with increased CDI risk, though the effect size was notably smaller than for PPIs 2. PPIs showed an adjusted OR of 1.8 (95% CI: 1.7-1.8), while H2-receptor antagonists had a lower but still elevated risk 2.
Guideline Perspective on Acid Suppression
The major clinical practice guidelines acknowledge this association but with important caveats:
The 2018 IDSA/SHEA guidelines note that the association between H2-blockers and CDI "remains controversial" 3. They emphasize that well-controlled studies suggest the association may result from confounding with underlying illness severity, non-CDI diarrhea, and duration of hospital stay rather than a direct causal relationship 3.
The 2019 WSES guidelines specifically state that PPIs show increased CDI risk even when compared to H2-antagonists (OR = 1.386,95% CI 1.152-1.668) 4. This meta-analysis of 50 studies provides strong evidence that the drug class matters.
Clinical Context and Risk Magnitude
Absolute vs Relative Risk
The absolute risk increase is modest. In the 2022 Japanese cohort study, among patients receiving antibiotics, the baseline CDI rate was 0.26% in controls versus 0.41% in the antiulcer agent group—a risk difference of only 0.09% 5. This small absolute risk should be weighed against clinical indications for acid suppression.
Duration-Dependent Risk
Risk increases with longer duration of acid suppressant use 1. This suggests that if famotidine is clinically necessary, using the shortest effective duration minimizes CDI risk.
Key Risk Factors to Consider
When prescribing famotidine, assess these concurrent CDI risk factors 2, 4:
- Antibiotic exposure (especially clindamycin, cephalosporins, fluoroquinolones, carbapenems)
- Advanced age (>65 years)
- Hospitalization duration
- Immunosuppression
- Recent chemotherapy
- Inflammatory bowel disease
- Corticosteroid use
Practical Recommendations
For patients requiring acid suppression:
- Famotidine is preferable to PPIs when either would be clinically appropriate, particularly in patients with other CDI risk factors 4, 1
- Discontinue unnecessary acid suppression—stewardship activities to stop unneeded H2-blockers are warranted 6, 4
- Use the shortest effective duration
- Avoid in patients with multiple concurrent CDI risk factors unless clearly indicated
Common pitfall: Continuing acid suppression "just in case" without reassessing clinical necessity. The 2019 WSES guidelines emphasize that consideration should be given to stopping acid suppressants when not necessary, especially in high-risk patients 4.
The Bottom Line
While famotidine does carry some CDI risk, it is substantially safer than PPIs in this regard and the absolute risk increase is small. The decision should be based on whether acid suppression is truly indicated—if it is, famotidine represents a lower-risk choice than PPIs for CDI prevention 1, 4.